Current Antiviral Therapy for Chronic Hepatitis B.
10.3346/jkms.2004.19.4.489
- Author:
Young Suk LIM
1
;
Dong Jin SUH
Author Information
1. Department of Internal Medicine, University of Ulsan, College of Medicine, Asan Medical Center, Seoul, Korea. djsuh@amc.seoul.kr
- Publication Type:Review
- Keywords:
Hepatitis B;
Hepatitis B Virus;
Interferon-alpha;
Lamivudine;
Adefovir Dipivoxil;
Antiviral Agents
- MeSH:
Adenine/*analogs & derivatives/therapeutic use;
Antiviral Agents/*therapeutic use;
Hepatitis B/*drug therapy;
Humans;
Interferon-alpha/therapeutic use;
Lamivudine/therapeutic use;
Phosphonic Acids/therapeutic use;
Reverse Transcriptase Inhibitors/therapeutic use
- From:Journal of Korean Medical Science
2004;19(4):489-494
- CountryRepublic of Korea
- Language:English
-
Abstract:
During the past decade, major breakthroughs have been achieved in treatment of chronic hepatitis B. Currently, three therapeutic agents are approved for chronic hepatitis B: interferon-alpha, lamivudine and adefovir dipivoxil. In patients with HBeAgpositive chronic hepatitis B, all of these drugs achieve HBeAg loss (24-33%) and anti-HBe seroconversion (12-30%) rates that are superior to those observed in untreated controls. Interferon-alpha has several drawbacks, such as the parenteral administration and the development of frequent and potentially serious side effects. Lamivudine is a safe drug with rare and generally mild side effects. Lamivudine induces an initial virological remission in 70-90% of patients, but only 30-40% of patients remain in remission after the third year due to progressively increasing viral resistance. The main advantage of adefovir dipivoxil is the rare emergence of resistance, which has been identified in less than 2% of patients at 2 yr of treatment. Adefovir is also effective against lamivudine-resistant strains. This review will focus on the natural history and recently gained knowledge on the treatment of chronic hepatitis B.
